CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


BiosensorsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1163 Ibrutinib Wiki 0.71
drug332 Best Practice Wiki 0.58

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D000741 Anemia, Aplastic NIH 1.00
D010265 Paraproteinemias NIH 1.00
D008998 Monoclonal Gammopathy of Undetermined Significance NIH 1.00
D008218 Lymphocytosis NIH 1.00
D009190 Myelodysplastic Syndromes NIH 0.58
D009369 Neoplasms, NIH 0.22

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0100827 Lymphocytosis HPO 1.00
HP:0012133 Erythroid hypoplasia HPO 1.00
HP:0002863 Myelodysplasia HPO 0.58
HP:0002664 Neoplasm HPO 0.22

There is one clinical trial.

Clinical Trials


1 Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study

Severe acute respiratory syndrome (SARS) SARS-Cov-2 disease (COVID-19) is an infectious disease caused by a coronavirus. The pandemic first described in Wuhan, China, has since spread across the whole world and caused dramatic strain on health care in many countries. Patients infected with the virus mostly report mild to moderate respiratory symptoms like shortness of breath and coughing, and febrile symptoms. It is of paramount importance to preserve health service capacity by identifying those with serious illness without transferring all infected patients to emergency rooms or Hospitals. In addition, it is important to identify seriously ill patients early enough and before they reach a point of deterioration where they can be extremely challenging to handle in both prehospital and hospital environment. The present study is designed to sample biosensor data from patients treated and observed at home due to mild and moderate SARS-Cov-2 disease. Such a system would be useful, both for the treatment of individual patients as well as for assessing the efficacy and safety of care given to these patients. Investigators intend to improve quality and safety of home care by continuous monitoring and a set of rules for follow-up. Investigators hypothesized that patients and local health system may benefit from the feedback of a simple monitoring system, which detects changes in respiration, temperature and circulation variables in combination with the patient's subjective experiences of care. Patients may be referred to hospitalization earlier. In the present study we will use live continuous and non-continuous biosensor data to monitor the development of vital parameters for Covid 19 patients compared with patients who are not monitored electronically (standard of care).

NCT04335097 COVID 19 Device: Biosensors

Primary Outcomes

Description: Day during home isolation it was stopped due to hospitalization

Measure: Stop home isolation

Time: 1 to 21 days

Description: 5 or >3 for one organ system

Measure: NEWS score

Time: 1 to 21 days

Secondary Outcomes

Description: Relevant vital clinical findings

Measure: Clinic at hospitalization

Time: At admittance hospital

Description: Symptoms developed during home isolation

Measure: Symptoms developed

Time: Duration of home isolation

Description: Their description of vital sign development

Measure: Relative/peers evaluation of the patient

Time: Duration of home isolation

Description: Referred to ICU, intubated, length of stay

Measure: Serious of symptoms at admittance hospital

Time: Hospital stay


No related HPO nodes (Using clinical trials)